Reports Q2 revenue $35.2M, consensus $33.0M. “This year, we’ve witnessed unprecedented interest in computational drug discovery and, as leaders in this field, we are excited by the growing recognition that computational approaches can transform pharmaceutical innovation,” said Ramy Farid, Ph.D., CEO. “During the second quarter, we made progress across all aspects of our business, building new capabilities in our platform, delivering revenue in line with our expectations and advancing our proprietary pipeline.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on SDGR:
- Schrodinger (NASDAQ:SDGR) Tanks after Q2 Numbers Disappoint
- Schrodinger options imply 9.6% move in share price post-earnings
- SDGR Earnings this Week: How Will it Perform?
- Blackrock Goes Big on These 2 ‘Strong Buy’ Stocks — Here’s Why You Should Follow
- Schrodinger price target raised to $52 from $38 at Morgan Stanley
